H.J. Metselaar

During my internship in Internal medicine, I got involved in clinical research in organ transplantation, especially CMV infection and immunosuppression and joined the Rotterdam liver transplant group in 1988. After the early pioneering years, the program slowly developed to the largest liver transplant program in the Netherlands, including a living donor liver transplant program and a translational research lab. Currently, around 80 liver transplants are performed annually, including 10 liver donor liver transplantations. The program is still expanding aiming at around 100 liver transplants annually.

My clinical research interest has changed over the years. From diagnostics and treatment of Cytomegalovirus infection and the role of immunoglobulin treatment in liver transplantation in the early years to more recently studying long term outcome and optimization of immunosuppression after liver transplantation.

Since 2012, I headed a team of talented clinicians, clinical and translational researches within the field of Hepatology and Liver Transplantation.

Medical Education          

1973-1979            Erasmus University, Rotterdam (medicine)

1980-1985            Internal Medicine

1985-1987            Intensive Care Medicine

2000-2002            Gastroenterology

Degrees

1979       Arts-Examen" (equivalent to M.D.), Erasmus University Rotterdam

2007       Professor of Liver Failure and Liver Transplantation (Full professor), Erasmus MC, Rotterdam

PhD thesis

1990       CMV infection after organ transplantation.

Teaching activities

• Teaching of bachelor and medical students
• Teaching of PhD students

Appointments

1980-1985 Resident Internal Medicine, University Hospital Rotterdam                                          

1985-1988 Consultant Physician Surgical Intensive Care Unit, University Hospital Rotterdam

1988-to date Consultant Physician Transplantation Unit, Dept. of Gastroenterology & Hepatology, Erasmus MC Rotterdam

2012-to date Head Section Hepatology

Other positions

-              Chairman Medical Ethics Committee, Erasmus MC

-              Board Dutch Society of Hepatology

-              Chairman Foundation for Gastroenterology and Hepatology Research (SLO)

1.  Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial. De Simone P, Nevens F, De Carlis, Metselaar, HJ, Beckebaum S, Saliba F, Jonas, S, Sudan D, Fung, Fischer, L for the H2304 Study Group. Am J Transplant 2012; 12; 3008-20. (166 times cited).
2. Modulation of the cellular immune system by intravenous immunoglobulin. Tha-In T, Bayry J, Metselaar H.J., Kaveri SV, Kwekkeboom J. Trends Immunol 2008; 29:608-15. (135 times cited).
3. A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation – PROTECT. Fischer L, Klempnauer J, Beckebaum S,  Metselaar HJ,  Neuhaus, P et al. A J Transplant 2012; 12: 1855-65 (108 times cited).
4. Conversion from a Calcineurin Inhibitor to Everolimus Therapy in Maintenance Liver Transplant Recipients: A Prospective, Randomized, Multicenter Trial. De Simone P, Metselaar HJ, Fischer L, Dumortier J et al. Liver Transplant 2009; 15: 1262-69. (94 times cited).
5. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Neuberger JM (Neuberger, Bechstein WO, Kuypers DRJ, Burra P, Citterio F, De Geest S,  Duvoux C,  Jardine AG, Kamar N, Kramer BK,  Metselaar HJ, Nevens F, Pirenne J, Rodriguez-Peralvarez ML, Samuel D,  Schneeberger S, Seron D, Trunecka P, Tisone G and van Gelder. Transplantation 2017;0101: S1-56. (66 times cited).

• Astellas (240 kE): Optimization of care of patient after liver transplantation
• Chiesi (340kE): Optimization of immunosuppression after liver transplantation
• Astellas (750 kE): Optimization of immunosuppression after liver transplantation

• Recurrence of PSC after liver transplantation
• Optimization of immunosuppression after liver transplantation